Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor
Angiogenesis · 2025
DOI: 10.1007/s10456-024-09966-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angiogenesis, 2025. Verfasst von Anbukkarasi Muniyandi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Choroidal Neovascularization, DNA-(Apurinic or Apyrimidinic Site) Lyase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Reduction-oxidation factor-1 or apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) is a crucial redox-sensitive activator of transcription factors such as NF-κB, HIF-1α, STAT-3 and others. It could contribute to key features of ocular neovascularization including inflammation and angiogenesis; these underlie diseases like neovascular age-related macular degeneration (nAMD). We previously revealed a role for Ref-1 in the growth of ocular endothelial cells and in choroidal neovascularization (CNV). Here, we set out to further explore Ref-1 in neovascular eye disease. Ref-1 was highly expressed in human nAMD, murine laser-induced CNV and Vldlr-/- mouse subretinal neovascularization (SRN). Ref-1's interaction with a redox-specific small molecule inhibitor, APX2009, was shown by NMR and docking. This compound blocks crucial angiogenic features in multiple endothelial cell types. APX2009 also ameliorated murine laser-induced choroidal neovascularization (L-CNV) when delivered intravitreally. Moreover, systemic APX2009 reduced murine SRN and downregulated the expression of Ref-1 redox regulated HIF-1α target carbonic anhydrase 9 (CA9) in the Vldlr-/- mouse model. Our data validate the redox function of Ref-1 as a critical regulator of ocular angiogenesis, indicating that inhibition of Ref-1 holds therapeutic potential for treating nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
- Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, M5S 3M2, Canada.
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Förderung
- NEI NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- National Eye Institute
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Riley Children's Foundation
Zitieren
APA
Muniyandi, A., Hartman, G. D., Sishtla, K., Rai, R., Gomes, C., Day, K., Song, Y., Masters, A. R., Quinney, S. K., Qi, X., Woods, H., Boulton, M. E., Meyer, J. S., Vilseck, J. Z., Georgiadis, M. M., Kelley, M. R., & Corson, T. W. (2025). Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor. Angiogenesis. https://doi.org/10.1007/s10456-024-09966-0
Vancouver
Muniyandi A, Hartman GD, Sishtla K, Rai R, Gomes C, Day K, et al. Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor. Angiogenesis. 2025. doi:10.1007/s10456-024-09966-0
BibTeX
@article{Muniyandi2025,
author = {Muniyandi, Anbukkarasi and Hartman, Gabriella D and Sishtla, Kamakshi and Rai, Ratan and Gomes, Cátia and Day, Kristina and Song, Yang and Masters, Andi R and Quinney, Sara K and Qi, Xiaoping and Woods, Hailey and Boulton, Michael E and Meyer, Jason S and Vilseck, Jonah Z and Georgiadis, Millie M and Kelley, Mark R and Corson, Timothy W},
title = {Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor},
journal = {Angiogenesis},
year = {2025},
doi = {10.1007/s10456-024-09966-0}
}
EUVIMED